It’s only fair to share… Inlexisertib CAS 2543673-19-2 MF C26H36F3N7O2, 535.62 4-(3-((2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one 4-[3-[[2-[2-ethyl-4-(4-methylpiperazin-1-yl)anilino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]propyl]-1,4-oxazepan-5-one serine/ threonine kinase inhibitor, antineoplastic, DCC 3116, JM2ZTM8S7S Inlexisertib is an orally bioavailable inhibitor of the serine/threonine-protein kinase ULK 1 and 2, with potential antineoplastic activity. Upon oral administration, inlexisertib targets and binds to ULK1/2. This inhibits cancer autophagy, which mutant RAS cancer …
Imocitrelvir
It’s only fair to share… Imocitrelvir CAS 343565-99-1 MFC26H29N5O7 MW523.5 g/mol ethyl (2E,4S)-4-{(2S)-2-[3-(5-methyl-1,2-oxazole-3-carboxamido)-2-oxopyridin-1(2H)-yl]pent-4-ynamido}-5-[(3S)-2-oxopyrrolidin-3-yl]pent-2-enoate ethyl (E,4S)-4-[[(2S)-2-[3-[(5-methyl-1,2-oxazole-3-carbonyl)amino]-2-oxo-1-pyridinyl]pent-4-ynoyl]amino]-5-[(3S)-2-oxopyrrolidin-3-yl]pent-2-enoateprotease inhibitor, antiviral, AG-7404, V-7404, AG 7404, V 7404, VQ1AN3OO42 Imocitrelvir is an investigational new drug that is being evaluated for the treatment of viral infections. It is a 3C protease inhibitor in picornaviruses. Originally developed by Pfizer for treating human rhinovirus infections,[1] this small molecule has shown promise against a broader range …
Ilantimod
It’s only fair to share… Ilantimod CAS 2242464-44-2 MF C18H18ClN5O3 MW 387.82 6-(4-chlorophenyl)-N-[(2S)-1-hydroxypropan-2-yl]-2-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydropyridazine-4-carboxamide (S)-6-(4-chlorophenyl)-N-(1-hydroxypropan-2-yl)-2-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydropyridazine-4-carboxamideimmunomodulator, BAY-2416964, BAY 2416964, Y87V4WXQ4Z Ilantimod is an orally available formulation containing a small molecule antagonist of the aryl hydrocarbon receptor (AhR; class E basic helix-loop-helix protein 76; bHLHe76) with potential immunomodulating and antineoplastic activities. Upon oral administration, ilantimod specifically binds to …
Icovamenib
It’s only fair to share… Icovamenib CAS 2448172-22-1 MF C31H34N8O3 MW 566.7 g/mol N-{4-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl}-4-{[(3R)-3-(prop-2-enamido) piperidin-1-yl]methyl}pyridine-2-carboxamide N-[4-(4-morpholin-4-yl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenyl]-4-[[(3R)-3-(prop-2-enoylamino)piperidin-1-yl]methyl]pyridine-2-carboxamidemenin-MLL (mixed-lineage leukemia) protein interaction inhibitor,antineoplastic, BMF-219, BMF 219, 2Z737MY35A, Menin-MLL inhibitor 21 Icovamenib is an investigational irreversible covalent inhibitor of menin. It is developed by Biomea Fusion for diabetes, lymphoma, leukemia, and multiple myeloma.[1][2][3]Icovamenib is an orally bioavailable, irriversible inhibitor of menin, an essential co-factor of oncogenic …
Ibrilatazar
It’s only fair to share… Ibrilatazar CAS 57818-44-7 MF C18H32O3 MW 296.4 g/mol rac-(2R)-(9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acidperoxisome proliferator activated receptor (PPAR) alpha and gamma agonist, antineoplastic, ABILITY PHARMA, ABTL 0812, alpha-Hydroxylinoleic acid, ABTL0812 Ingredient UNII CAS InChI Key ABTL-0812 Sodium X1840C8161 Not Available VFXKYDDSDQXKLC-NBTZWHCOSA-M Ibrilatazar also known as α-hydroxylinoleic acid is a small-molecule, experimental cancer drug being developed by Ability Pharmaceuticals.[1] …
Glovadalen
It’s only fair to share… Glovadalen CAS 2576359-31-2 MF C24H27Cl2N3O3 MW 476.4 g/mol 2-(3,5-dichloro-1-methyl-1H-indazol-4-yl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(2-hydroxypropan-2-yl)-1-methyl-3,4-dihydroisoquinolin-2(1H)-yl]ethan-1-one, 2-(3,5-dichloro-1-methylindazol-4-yl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(2-hydroxypropan-2-yl)-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]ethanonedopamine D1 receptor positive allosteric modulator, Phase 2, Parkinson’s disease, UCB-0022, UCB 0022, H8T5VKH4CZ Glovadalen (developmental code name UCB-0022) is a dopamine D1 receptor positive allosteric modulator which is under development for the treatment of Parkinson’s disease.[1][2][3][4][5][6] It has been found to potentiate the capacity of dopamine to activate the D1 receptor …
Girocitinib
It’s only fair to share… Girocitinib CAS 2222137-79-1 MFC17H18N4O3 MW 326.36 2-[(2R,5S)-5-[4-[(1R)-1-hydroxyethyl]-12-oxa-3,5,8-triazatricyclo[7.3.0.02,6]dodeca-1,4,6,8,10-pentaen-3-yl]oxan-2-yl]acetonitrile [(2R,5S)-5-{2-[(1R)-1-hydroxyethyl]-1H-furo[3,2-b]imidazo[4,5-d]pyridin-1-yl}oxan-2-yl]acetonitrile 2-((2R,5S)-5-(2-((R)-1-hydroxyethyl)-1H-furo[3,2-b]imidazo[4,5-d]pyridin-1-yl)tetrahydro-2H-pyran-2-yl)acetonitrileJanus kinase inhibitor, anti-inflammatory, A0IES9T8GO In an era where targeted therapies are redefining the landscape of medical treatment, Girocitinib emerges as a beacon of hope for many. This innovative drug, developed by leading pharmaceutical research institutions, primarily targets specific proteins involved in disease progression. …
Gildeuretinol
It’s only fair to share… Gildeuretinol Retin-20,20,20-d3-ol CAS118139-35-8 MF C20H272H3O, MW 289.5 g/mol (2E,4E,6E,8E)-3-(2H3)methyl-7-methyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraen-1-ol; (20,20,20-2H3)retinol (2E,4E,6E,8E)-7-methyl-3-(trideuteriomethyl)-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraen-1-olvitamin A analogue, Orphan Drug, Stargardt disease, breakthrough therapy, Pediatric Rare Disease designations, ALK-001, KL-49, ALK 001, KL 49 Gildeuretinol is an investigational new drug being developed by Alkeus Pharmaceuticals, Inc. for the treatment of retinal diseases, particularly Stargardt disease and geographic atrophy secondary to age-related macular degeneration (AMD). Stargardt disease is …
Frevecitinib
It’s only fair to share… Frevecitinib CAS 1299417-07-4 MF C22H21N7O2 MW 415.4 g/mol 3-[(3S)-3-(1-methyl-2-oxo-5-pyrazolo[1,5-a]pyridin-3-ylimidazo[4,5-b]pyridin-3-yl)piperidin-1-yl]-3-oxopropanenitrile 3-{(3S)-3-[1-methyl-2-oxo-5-(pyrazolo[1,5-a]pyridin-3-yl)-1,2-dihydro-3H-imidazo[4,5-b]pyridin-3-yl]piperidin1-yl}-3-oxopropanenitrileJanus kinase inhibitor, anti-inflammatory, 5N5L287M8T, KN 002, KN-002 Single and Multiple Ascending Dose Study of KN-002 CTID: NCT05006521 Phase: Phase 1 Status: Completed Date: 2024-08-07 SYN https://patentscope.wipo.int/search/en/detail.jsf?docId=US210080653&_cid=P11-MH2U9I-58146-1 It has now been found that a drug substance disclosed in WO2011/051452, namely the compound (S)-3-(3-(1-methyl-2-oxo-5-(pyrazolo[1,5-a]pyridine-3-yl)-1H-imidazo[4,5-b]pyridine-3(2H)-yl)piperidin-1-yl)-3-oxopropanenitrile having the structure …
Remibrutinib
It’s only fair to share… Remibrutinib CAS 1787294-07-8 N-[3-[6-amino-5-[2-[methyl(prop-2-enoyl)amino]ethoxy]pyrimidin-4-yl]-5-fluoro-2-methylphenyl]-4-cyclopropyl-2-fluorobenzamide MW 507.5 g/mol, MF C27H27F2N5O3 APPROVALS 2025, FDA 2025, 9/30/2025, To treat chronic spontaneous urticaria in adults who remain symptomatic despite H1 antihistamine treatment Remibrutinib, sold under the brand name Rhapsido, is a medication used for the treatment of chronic spontaneous urticaria.[1] Remibrutinib is an oral, small molecule kinase inhibitor that inhibits Bruton’s tyrosine kinase (BTK).[1] It is …